Tiglutik® - a different riluzole therapy for ALS


TIGLUTIK is an oral suspension (mildly thick liquid) formulation of riluzole. It was developed specifically to meet the needs of people with ALS. Since TIGLUTIK is approved for use throughout all stages of ALS, patients can start taking it as soon as they are diagnosed with ALS. TIGLUTIK is the only formulation of riluzole approved for both oral and PEG tube administration.

TIGLUTIK is for People Who Have Difficulty Swallowing

Swallowing requires many nerves and muscles to work together so food and beverages can move from the mouth to the stomach. ALS often affects the nerves and muscles that help us swallow. In many people, ALS causes a medical condition called dysphagia. Dysphagia means difficulty in swallowing. It is the sensation of abnormal swallowing.

One of the biggest fears that people with ALS have is choking. Dysphagia does not happen overnight. Often, people with ALS don’t notice they have difficulty swallowing. They automatically adjust to the small day-to-day changes that occur to the nerves and muscles that control swallowing. Dysphagia is very common in ALS and affects about 85% of people.

For more information, click here to visit the TIGLUTIK website.

EDW (Formerly ITF) received FDA-approval on September 6, 2018, for TIGLUTIK, the first and only liquid oral suspension of riluzole for the treatment of ALS.

EDW (Formerly ITF) received FDA-approval on December 13, 2019, to broaden the existing label for TIGLUTIK to include administration via percutaneous endoscopic gastrostomy (PEG) tubes for the treatment of ALS.